Evidence map›Paper›PMID 27461342›Full record

ArticleHuman genomics2016

Hypomethylation coordinates antagonistically with hypermethylation in cancer development: a case study of leukemia.

Garima Kushwaha, Mikhail Dozmorov, Jonathan D Wren, Jing Qiu, Huidong Shi, Dong Xu

Open access · goldAbstract read
In one paragraph

Article in Human genomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Garima KushwahaChristopher S. Bond Life Sciences Center, University of Missouri, Columbia, MO, 65211, USA.
Mikhail DozmorovDepartment of Biostatistics, Virginia Commonwealth University, Richmond, VA, 23225, USA.
Jonathan D WrenArthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 73104, USA.
Jing QiuDepartment of Applied Economics & Statistics, University of Delaware, Newark, DE, 19716, USA.
Huidong ShiGRU Cancer Center, Georgia Regents University, Augusta, GA, 30912, USA. hshi@gru.edu.
Dong XuChristopher S. Bond Life Sciences Center, University of Missouri, Columbia, MO, 65211, USA. xudong@missouri.edu.
University of Missouri · USGeorgia Regents Medical Center · USOklahoma Medical Research Foundation · USUniversity of Delaware · USVirginia Commonwealth University · US

Funding

Genome-scale anaylsis of DNA methylation in CpG Islands with bisulfite sequencingR01DA025779 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHI, HUIDONG, ZHANG, KUN · 2008 to 2011
$2.3M
Application of 454 Sequencing to Cancer EpigenomicsR33CA134304 · NCI · AUGUSTA UNIVERSITY · PI SHI, HUIDONG · 2009 to 2011
$942k
NCI NIH HHS R33 CA134304NIDA NIH HHS R01 DA025779
6 · The paper itself

Abstract

backgroundMethylation changes are frequent in cancers, but understanding how hyper- and hypomethylated region changes coordinate, associate with genomic features, and affect gene expression is needed to better understand their biological significance. The functional significance of hypermethylation is well studied, but that of hypomethylation remains limited. Here, with paired expression and methylation samples gathered from a patient/control cohort, we attempt to better characterize the gene expression and methylation changes that take place in cancer from B cell chronic lymphocyte leukemia (B-CLL) samples.

resultsAcross the dataset, we found that consistent differentially hypomethylated regions (C-DMRs) across samples were relatively few compared to the many poorly consistent hypo- and highly conserved hyper-DMRs. However, genes in the hypo-C-DMRs tended to be associated with functions antagonistic to those in the hyper-C-DMRs, like differentiation, cell-cycle regulation and proliferation, suggesting coordinated regulation of methylation changes. Hypo-C-DMRs in B-CLL were found enriched in key signaling pathways like B cell receptor and p53 pathways and genes/motifs essential for B lymphopoiesis. Hypo-C-DMRs tended to be proximal to genes with elevated expression in contrast to the transcription silencing-mechanism imposed by hypermethylation. Hypo-C-DMRs tended to be enriched in the regions of activating H4K4me1/2/3, H3K79me2, and H3K27ac histone modifications. In comparison, the polycomb repressive complex 2 (PRC2) signature, marked by EZH2, SUZ12, CTCF binding-sites, repressive H3K27me3 marks, and "repressed/poised promoter" states were associated with hyper-C-DMRs. Most hypo-C-DMRs were found in introns (36 %), 3' untranslated regions (29 %), and intergenic regions (24 %). Many of these genic regions also overlapped with enhancers. The methylation of CpGs from 3'UTR exons was found to have weak but positive correlation with gene expression. In contrast, methylation in the 5'UTR was negatively correlated with expression. To better characterize the overlap between methylation and expression changes, we identified correlation modules that associate with "apoptosis" and "leukocyte activation".

conclusionsDespite clinical heterogeneity in disease presentation, a number of methylation changes, both hypo and hyper, appear to be common in B-CLL. Hypomethylation appears to play an active, targeted, and complementary role in cancer progression, and it interplays with hypermethylation in a coordinated fashion in the cancer process.

Indexed as

DNA MethylationBiomarkers, TumorCpG IslandsEpigenesis, GeneticGene Expression ProfilingGene Expression Regulation, LeukemicGene OntologyGenetic HeterogeneityGenome-Wide Association StudyHistonesHumansLeukemia, Lymphocytic, Chronic, B-CellMethylationModels, GeneticPromoter Regions, GeneticBiomarkers, TumorHistones3′UTRCancerCLLDNA methylationEnhancerEpigenetic regulationHypomethylationSignaling pathway

Identifiers

PMID27461342
PMCPMC4965721
OpenAlexW2490712594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.